ORLANDO, FL / ACCESSWIRE / October 3, 2019 / Florida-based biopharma CTD Holdings (OTCQB:CTDH) received a buy recommendation in the September 30 edition of Frazier, Browne and Mayer's Strategic Allocator, a monthly research and advisory journal for RIAs and high net-worth individuals.
First OTC Stock Recommendation from Strategic Allocator
In recommending CTD Holdings' shares, Strategic Allocator cited the company's upcoming Phase III trial of its treatment for Nieman-Pick Disease Type C (NPC), a fatal genetic cholesterol metabolism disease, and the potential for the same drug, Trappsol® Cyclo™, to be used effectively in treating Alzheimer's Disease.
This is the first OTC stock Strategic Allocator has recommended its readers buy, according to publisher David Frazier.
Could CTD Holdings have a Treatment for Alzheimer's?
CTD Holdings has been intravenously administering its proprietary Trappsol® Cyclo™ product to an Alzheimer's patient for more than a year.
In a required annual report to the FDA filed in May 2019, the company reported data that suggests a positive safety profile in the Alzheimer's patient, overall stabilization of disease, and improvement in certain behavioral aspects of the disease. Given that persons with Alzheimer's Disease dementia are generally expected to decline during a one-year timeframe, the results with this patient are extremely promising.
Preparations for Clinical Trials Underway
More recently, the company announced a new collaboration with the Chattanooga Center for Neurologic Research (CCNR) based in Chattanooga, Tennessee.
CCNR is a biomedical research company led by globally recognized vascular neurologist Thomas G. Devlin, MD, PhD. In close partnership with Erlanger Health System and the University of Tennessee College of Medicine, Dr. Devlin has spearheaded the launch of various biotechnology companies whose commercialized products are having widespread impact on neurologic disease.
The collaboration is expected to lead to selection of CCNR and the Erlanger Health System as a site in CTD Holdings' clinical trial in Alzheimer's Disease, now in the design stage. As a first step in the collaboration, CCNR and CTD Holdings representatives will exchange confidential information on priority scientific topics and clinical capacity.
Strategic Allocator, which recommended its readers buy CTD Holdings shares at up to $0.25 for a potential "exponential increase in the price of the company's stock - an increase of up to 30 times its current price, or potentially even more than that, within the next five years," isn't the first outsider to understand the opportunity with CTD Holdings.
Board Members Invest $10M+ into CTD Holdings
Board members at CTD Holdings, including multiple outside directors, have invested more than $10 million into the company in recent years, including more than half a million shares purchased this summer alone.
Board member Markus Sieger, President and CEO of Polpharma Group, purchased 100,000 shares in August, increasing his total position to more than 4.5 million shares. Polpharma is among the top 20 generic drug manufacturers in the world. Its portfolio includes about 600 products and another 200 in development.
Patrick Ostronic, an officer of US Pharmacia International and CFO of its parent company, The USP Group, personally purchased 350,000 shares of CTDH in the weeks following the company announcing its plans to launch an Alzheimer's trial. As of the latest filing, Ostronic himself owned more than 1.3 million shares of CTDH. USP has been a trendsetter in the OTC medicine market for over 20 years and is currently the leading company in the OTC sector of the Polish pharmaceutical market, employing around 700 people across Eastern Europe and the United States with a portfolio of more than 100 products.
Former President & COO of Colgate-Palmolive Owns 2.5M+ Shares
Also serving on CTDH's board is William Shanahan, the retired President and COO of Colgate-Palmolive. Shanahan joined CTDH's board in 2016 and now owns more than 2.6 million shares of CTDH as of the latest filings, which include his 800,000 share purchase in May 2019 and his purchase of 415,000 shares in August and September 2019.
Board Members See Long-Term Potential
We spoke with one of these board members, Markus Sieger, to learn more about his involvement in CTD Holdings.
Sieger first learned of CTD Holdings from long-time acquaintance and Chairman and CEO of the company, Scott Fine.
Commenting on why he first got involved in CTD Holdings, Sieger stated, "First, I looked at the technology and was impressed with the results in treating the Hempel twins' Niemann Pick Type C disease. There was simply no treatment for Niemann Pick disease prior to our drug. The fact that these twins were kept alive with good quality of life until years beyond their normal disease progression would suggest I found astounding."
Sieger has been a director of the company since February 2014. Since June 2016, he has been the President and CEO of Polpharma Group, one of the leading pharmaceutical generics companies operating in the Central and Eastern Europe region.
"I also like the fact that Scott Fine, the CEO, has surrounded himself with seasoned professionals and investors," continued Sieger. "The confidence that US Pharmacia has invested just under $5 million in the company and to have Armistice as a recognized healthcare investor in the latest round is helpful. The Alzheimer's program indicates our capacity to expand our clinical programs utilizing our science and knowledge of cyclodextrins."
"All of us understand that Biotechnology investing is a risk, we at CTD understand this, we see the potential opportunity as well," concluded Sieger.
Learn more about CTDH, its work in Alzheimer's, and its clinical trials for NPC, by visiting CTDHinfo.com.
Additional information available at the company's website and in their latest investor presentation.
For a brief overview of CTD Holdings, watch this video: https://youtu.be/UvrTNdhj-2w.
About RedChip Companies, Inc.
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 27 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered on-line weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; investor webinars and group calls; a globally-televised show, "The RedChip Money Report," which airs in 149 million homes globally on Bloomberg International; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Disclaimer: RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
CTD Holdings (CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee of between $15,000 and $30,000 for RedChip investor awareness services and consulting services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
Contact:
Dave Gentry, CEO
RedChip Companies
407-644-4256
[email protected]
SOURCE: CTD Holdings